DCP Capital is a private equity firm established in 2017 and headquartered in Beijing, China, with additional offices in Hong Kong and New York. The firm specializes in buyout investments, focusing on family-owned businesses and public companies primarily within Asia, particularly Greater China. DCP Capital targets various sectors including consumer products and services, healthcare, agriculture, telecommunications, and industrial technology, among others. The firm typically invests at least $100 million in each opportunity and aims to capitalize on special situations and industry reorganizations. With a team that has extensive experience from leading private equity firms, DCP Capital is well-positioned to navigate diverse economic cycles while pursuing its investment strategy.
Datong Insurance is a professional third-party financial insurance service organization. Datong’s subsidiaries include Datong Insurance Sales Service Co., Ltd., Beijing Datong Insurance Brokers Co., Ltd., among which Datong Insurance Sales Service Co., Ltd. is approved by the China Insurance Regulatory Commission. The first national insurance professional sales and service organization approved to be established. At present, the Datong service network has covered more than 20 provinces and municipalities across the country.
Adopt A Cow
Private Equity Round in 2021
Adopt A Cow is a fast-growing, direct-to-consumer dairy company in China that integrates digital solutions into its core operations.
Furong Xingsheng, founded in 2009 and based in Changsha, China, operates convenience stores that serve the local community's daily needs. The company has evolved into a community shopping platform known as Xingsheng Youxuan, which was established in 2018. This platform utilizes a hybrid retail model that combines online ordering with offline pick-up, allowing consumers to access a variety of fresh products. The offerings include fresh vegetables, fruits, meat and poultry, seafood, staple foods, seasonings, and other household items. Through its network of convenience stores, Furong Xingsheng aims to provide convenient access to essential goods for consumers in the region.
Fenbi Ltd is a vocational education and training service provider based in China, specializing in career test preparation. The company offers a wide range of tutoring courses aimed at adult students seeking to excel in recruitment and qualification examinations for government-sponsored institutions and various professions. Fenbi assists college graduates and professionals in navigating the competitive selection processes and obtaining necessary qualifications. The business primarily generates revenue through classroom-based tutoring services, complemented by the sale of educational books. Fenbi's focus on vocational education positions it as a key player in helping individuals advance their careers in a variety of fields.
Founded in 2012, Yuanfudao is the largest online live courseplatform servicing primary and secondary school students in China. With a paying userbase of over 1 million, Yuanfudao offers a comprehensive curriculum spanning fromprimary school English, Mathematical Olympiad to all-subject courses in secondaryschool. Its unique online feature and large pool of quality teachers enable students toaccess live online tutoring at home taught by national renowned teachers, benefitinghundreds of thousands of students across the country.
Broncus Medical develops innovative diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company offers a range of products, including the Archimedes System, which features bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning and navigation, and the Lungpoint Virtual Bronchoscopic Navigation system that enables real-time navigation within the lungs for biopsy procedures. Additionally, Broncus is advancing its Exhale product line, which includes the Airway Bypass procedure, a minimally-invasive treatment for homogeneous emphysema, a prevalent form of the disease. The company is currently conducting the pivotal EASE Trial to evaluate this treatment. Founded in 1997 and originally named Broncus Technologies, the company is headquartered in San Jose, California, with additional operations in Shanghai, China, and Mountain View, California. Broncus Medical focuses on addressing the unmet medical needs in interventional pulmonology, improving the diagnosis and treatment of lung cancer and chronic obstructive pulmonary disease (COPD).
Tonghua Dongbao Pharmaceutical Co., Ltd. is a Chinese company focused on the research, development, manufacturing, and marketing of pharmaceutical products primarily for diabetes and cardiovascular diseases. The company's product portfolio includes various insulin analogues, such as insulin glargine and insulin aspart, as well as oral hypoglycemic agents and specific capsules for brain and heart health. Additionally, the firm is advancing several biopharmaceuticals, including recombinant human interferon injections for chronic hepatitis and a recombinant human growth hormone for growth hormone deficiency, which are in various clinical stages. Beyond pharmaceuticals, Tonghua Dongbao also produces building materials, such as plastic windows. Established in 1985 and headquartered in Tonghua, China, the company has formed strategic partnerships to enhance its product offerings and market reach.
Far East Horizon is a financial services organization. Far East Horizon is devoted to providing its customers with tailored industrial integrated operation services through continual innovation of products and services. Far East Horizon develops industry integrated operation services such as financial services, industrial investment and operation, operational leasing ,trade brokering, management consulting and construction services for multiple fields including health, packaging, transportation, construction, machinery, education, textiles, electronic information and public utilities. By matching up the organizational operation of financial resources with the discovery and cultivation of industrial resources, Far East Horizon creates an operational advantage with the characteristics of joint development of finance and industry.
Venus MedTech (Hangzhou) Inc. specializes in the development and sale of transcatheter heart valve medical devices, operating both in Mainland China and internationally. Founded in 2009 and headquartered in Hangzhou, the company offers a range of innovative products, including the VenusA-Valve for treating severe aortic stenosis, the VenusP-Valve for addressing right ventricular outflow tract dysfunction, as well as catheter systems like the V8/TAV8 for balloon aortic valvuloplasty. Additionally, Venus MedTech has developed the TriGUARD3, a cerebral embolic protection device designed to reduce the risk of cerebral damage during heart procedures. The company is also working on product candidates such as VenusA-Plus and VenusA-Pilot, along with transcatheter mitral and tricuspid valve replacement solutions. Positioned within the Hangzhou National High-tech Industrial Development Zone, Venus MedTech aims to meet the growing clinical needs for interventional artificial cardiac valves, a field that is gaining recognition and demand in China and beyond.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.